Abstract 7617: A multi-omic liquid biopsy for the earlier detection of ovarian cancer

Abstract Background: Ovarian cancer has one of the highest mortality rates among gynecologic cancers, largely because more than 70% of cases are diagnosed at more advanced stages. Early-stage ovarian cancer, by contrast, has a five-year survival rate above 90%. Currently, there are no approved population-wide screening tests for ovarian cancer, due to ineffective testing options highlighting the urgent need for better early detection tools. Novel liquid biopsy technologies offer a promising path to identify ovarian cancer early, when treatment is far more effective. Methods: This study explored the ability of a multi-omic liquid biopsy as an alternative strategy for ovarian cancer detection. The technology utilizes infrared (IR) spectroscopy and interrogates a blood sample with IR light to produce a distinctive signature that is sensitive to the signals of cancer. In this proof-of-concept study, 125 ovarian cancer patients were classified against 260 female symptomatic patients with a non-cancer diagnosis. Blood was obtained from patients before surgical resection or the start of other anti-cancer therapies. Blood serum samples were analyzed by the Dxcover® Liquid Biopsy Platform and classified with machine learning algorithms. These trained algorithms are then independently tested on an additional clinical dataset. Results: The receiver operating characteristic (ROC) curve reported an area under the curve (AUC) value of 0.86. The sensitivity-tuned algorithm reported 92% sensitivity with 54% specificity, and the specificity-tuned model reported 58% sensitivity with 90% specificity. Importantly, the diagnostic algorithm was unaffected by cancer stage. The detection rates were 97% stage I, 86% stage II, 92% stage III and 100% stage IV, for the high sensitivity model. Validation testing provided additional confirmation of diagnostic ability in the intended use population. Conclusions: Detecting ovarian cancer earlier improves prognosis and survival rates of affected patients. There is a low barrier to integrating the blood test into existing diagnostic pathways since the technology is simple to use, minute sample volumes are required, and results can be provided rapidly. This liquid biopsy represents an alternative strategy, particularly for high-risk populations, that may address the gap in ovarian cancer diagnostics. Citation Format: James M. Cameron, Holly Butler, David Palmer, Rose McHardy, Matthew Baker. A multi-omic liquid biopsy for the earlier detection of ovarian cancer abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7617.